Latest Hematological malignancy Stories
Data Show 84% Progression-Free Survival Rate at One Year and Improvement in Quality of Life SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
- Note: This press release corresponds to abstracts 627 and 1998. SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced by Pharmacyclics, Inc.
- AbbVie Presents for the First Time Results from the Venetoclax Phase 2 Program in Acute Myelogenous Leukemia NORTH CHICAGO, Ill., Dec.
TG02 demonstrates ability to mobilize difficult-to-kill leukemic stem cells and render them vulnerable to chemotherapy. San Diego, California (PRWEB) December
SAN FRANCISCO, Dec.
U.S.-Based Registry Will Enhance Clinical Knowledge of and Explore Treatment Options for CLL Patients SUNNYVALE, Calif., Dec. 5, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
SUNNYVALE, Calif., Dec.
WHITE PLAINS, N.Y., Dec.
Funds Will Support Research Into Safety and Efficacy of Genetically Unmatched Cord Blood Stem Cell Transplantations Using a Myeloablative Preparative Regimen. NEW YORK, Dec.
KB004 Phase 1/2 Clinical Data in Hematologic Malignancies to be presented at the 56th American Society of Hematology Annual Meeting and Exposition SOUTH SAN FRANCISCO, Calif., Nov.
- The abrogation of a law by a higher authority; annulment.